Popular terms

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents



      

This page is updated frequently with new Autoimmune Disease-related patent applications.




Date/App# patent app List of recent Autoimmune Disease-related patents
04/07/16
20160096891 
 Anti-b7-h5 antibodies and their uses patent thumbnailAnti-b7-h5 antibodies and their uses
The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the b7-h5 ligand of the b7-h5:cd28h pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.. .
The Johns Hopkins University


04/07/16
20160095910 
 Self-assembling synthetic proteins patent thumbnailSelf-assembling synthetic proteins
The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host..

04/07/16
20160095895 
 Highly concentrated formulations of soluble fc receptors patent thumbnailHighly concentrated formulations of soluble fc receptors
The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


04/07/16
20160095839 
 Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions patent thumbnailMethod of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.


04/07/16
20160095835 
 Compositions containing omega-3 oil and uses thereof patent thumbnailCompositions containing omega-3 oil and uses thereof
The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.


03/31/16
20160090627 
 Compositions for detecting human interferon-alpha subtypes and methods of use patent thumbnailCompositions for detecting human interferon-alpha subtypes and methods of use
The invention provides highly sensitive, specific and efficient quantitative real-time pcr compositions, methods and assay kits to detect at least one ifn subtype and/or ifn subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an ifn subtype of interest avoid spurious detection of degraded mrna and enhances the correlation between the ifn subtype that is measured by the assays of the invention and the protein that is actually expressed.
United States Department Of Health & Human Services


03/24/16
20160084844 
 Methods of identifying glycopeptides recognized by disease-associated auto-antibodies patent thumbnailMethods of identifying glycopeptides recognized by disease-associated auto-antibodies
Methods for identifying glycopeptides and more particularly glycopeptide epitopes that are specifically recognized by disease-associated auto-antibodies are provided. In some aspects the auto-antibodies are cancer-associated or autoimmune disease associated.
Glycozym, Inc.


03/24/16
20160083473 
 Bispecific constructs and their use in the treatment of various diseases patent thumbnailBispecific constructs and their use in the treatment of various diseases
The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


03/24/16
20160083369 
 Heterocyclic compounds and use thereof patent thumbnailHeterocyclic compounds and use thereof
Heterocyclic compounds of formula (i) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation.
National Health Research Institutes


03/24/16
20160082017 
 Estriol therapy for multiple sclerosis and other autoimmune diseases patent thumbnailEstriol therapy for multiple sclerosis and other autoimmune diseases
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/17/16
20160075999 

Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases


A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell.
Gwo Xi Stem Cell Applied Technology Co., Ltd.


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160074505 

Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases


A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

03/17/16
20160074499 

Anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing culture medium of adsc-t cells in which t-antigen is introduced into adipose-derived stem cell as active ingredient


The present invention relates to an anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing a culture medium of adipose-derived stem cell-t (adsc-t) cells as an active ingredient, in which t-antigen is introduced into an adipose-derived stem cell. The culture medium of adsc-t cells, according to the present invention, has remarkable effects for treating or inhibiting inflammation by alleviating atopic dermatitis, which is an autoimmune disease, and inhibiting nf-κb activities through an increase of an iκbα expression.
Changwon National University Industry Academy Cooperation Corps


03/10/16
20160069896 

Diagnosis of autoimmune diseases using a specific antibody profile


Methods and kits for diagnosing systemic lupus erythematosus (sle) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing sle or scleroderma in a subject..
Yeda Research And Development Co., Ltd.


03/10/16
20160068809 

Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants


The invention relates to the use of 1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of indoleamine 2,3-dioxygenase (ido) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.. .
Idogen Ab


03/10/16
20160068534 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068524 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068522 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/03/16
20160060700 

Copy number variations and autoimmune diseases


This disclosure describes methods of determining the copy number of fcgr3a and/or fcgr3b in the genome of an individual, which is shown herein to be statistically significantly associated with an increased risk of the individual developing an autoimmune disease.. .
Regents Of The University Of Minnesota


03/03/16
20160060299 

Macrocyclic therapeutic agents and methods of treatment


The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Inc.


03/03/16
20160060264 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/03/16
20160060237 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (i)..
Bristol-myers Squibb Company


03/03/16
20160058874 

Cyclodextrin-based polymers for therapeutic delivery


Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.


03/03/16
20160058792 

Methods and compositions of treating autoimmune diseases


Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the il 27/ectonucleotidase cd39 axis signaling.
The Brigham And Women's Hospital, Inc.


03/03/16
20160058742 

Fused amino pyridine as hsp90 inhibitors


The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.


02/25/16
20160053007 

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies


Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


02/25/16
20160052888 

Substituted bicyclic compounds


And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

02/25/16
20160052876 

Cryopyrin inhibitors for preventing and treating inflammation


Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases.. .
Virginia Commonwealth University


02/25/16
20160051671 

Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and anti-cd20 agents for the treatment of autoimmune diseases. One preferred method is where the blys antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Zymogenetics, Inc.


02/25/16
20160051573 

Structure and use of 5' phosphate oligonucleotides


Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by rig-i, leading to the induction of type i ifn, il-18 and il-1β production. Bacterial rna also induces type i ifn production.
Rheinische Friedrich-wilhelms-universität Bonn


02/25/16
20160051553 

Molecular and herbal combinations with methotrexate for treating diseases and inflammatory ailments


A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a methotrexate regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal, Ltd.


02/18/16
20160046714 

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity


The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of t cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. Type 1 diabetes or insulin-dependent diabetes mellitus (iddm)) and multiple sclerosis) through the use of anti-human cd3 antibodies.
Macrogenics, Inc.


02/18/16
20160046691 

Novel epitope for switching to th2 cell and use thereof


The present invention relates to a novel epitope to convert t cell to type 2 helper t (th2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody..

02/18/16
20160046661 

Ras inhibitors and uses thereof


Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.


02/18/16
20160046619 

Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities


Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..

02/18/16
20160046602 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

02/18/16
20160045550 

Method of expanding double negative t cells


A method of expanding double negative t cells in culture is described. The method comprises (a) providing a starting sample comprising dn t cells or precursors thereof; (b) substantially depleting cd8+ and cd4+ t cells from the starting sample; (c) culturing the sample from step (b) with an immobilized t cell mitogen in a culture medium comprising an agent that can stimulate dn t cell growth (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the t cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble t cell mitogen.
University Health Network


02/18/16
20160045503 

Formulations containing reversible covalent compounds


Oral pharmaceutical formulations comprising reversible covalent compounds having a michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.. .
Principia Biopharma Inc.


02/11/16
20160039905 

B7-h4 fusion proteins and methods of use thereof


Fusion proteins containing b7-ii4 polypeptides are disclosed. The b7-h4 fusion proteins can include full-length b7-h4 polypeptides, or can contain a fragment of a full-length b7-h4 polypeptide, including some or all of the extracellular domain of the b7-h4 polypeptide.
Amplimmune, Inc.


02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/11/16
20160039784 

Pyrazole derivative


Provided are a compound expressed by formula (i) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [in the formula, a, x, y, z, r, and r1 have the meaning set forth in claim 1]..
Teijin Pharma Limited


02/11/16
20160038503 

Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives


The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell lymphoma).

02/11/16
20160038496 

Novel formulations of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


02/04/16
20160034637 

Method for evaluating an immunorepertoire


Disclosed is a method for amplifying rna from t and b-cell populations and using the amplified rna products to evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.. .
Cb Biotechnologies, Inc.


02/04/16
20160033528 

Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof


Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California


02/04/16
20160032003 

Therapeutic use of anti-cd22 antibodies for inducing trogocytosis


Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-b cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention.
Immunomedics, Inc.


02/04/16
20160031934 

Dipeptide and tripeptide epoxy ketone protease inhibitors


Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of formula (x): and pharmaceutically acceptable salts and compositions including the same.
Onyx Therapeutics, Inc.


02/04/16
20160031891 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

02/04/16
20160030439 

Methods for the treatment of autoimmune diseases


The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


01/28/16
20160024508 

Method for identifying biologically active oligonucleotides capable of modulating the immune system


The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis


The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 

Anti-cd52 antibodies


Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 

Llt-1 antibodies with new functional properties


The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024212 

Humanized anti-hla-dr antibodies


The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.


01/28/16
20160024211 

Methods of modulating immune function


Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of b7-h7 to b7-hrcr, or the binding of b7-h2 to either icos, cd28, or ctla-4.
The Johns Hopkins University


01/28/16
20160024183 

Synthetic peptides for the treatment of autoimmune diseases


The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160022788 

Compositions and methods for treating autoimmune diseases


The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences




Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5414

5606

0 - 1 - 103